



Glaukos Announces Participation in Upcoming Investor Conferences

2020-11-11

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the following upcoming investor conferences:

- Berenberg U.S. CEO Conference on Thursday, November 12, 2020 (one-on-one and group meetings only)
- Stephens Annual Investment Conference on Thursday, November 19, 2020 at 8:00 a.m. PST
- Piper Sandler 32nd Annual Healthcare Conference (a pre-recorded fireside chat presentation will be available for viewing beginning on Monday, November 23, 2020; management will participate in one-on-one and group meetings on Wednesday, December 2, 2020)

A live and archived webcast for these event, where applicable, will be available in the Investors section of the Glaukos website at <http://investors.glaukos.com>.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the *iStent*[®], its first MIGS device, in the United States in July 2012, its next-generation *iStent inject*[®] device in the United States in September 2018 and most recently, its *iStent inject*[®] W device in the United States in October 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201111005692/en/): <https://www.businesswire.com/news/home/20201111005692/en/>

Chris Lewis
Director, Investor Relations, Corporate Strategy & Development
(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation